Shortwave Life Sciences is a biopharmaceutical company developing novel drug combinations and delivery methods to treat patients suffering from life-threatening mental health disorders. We identify, operate and create value from early-stage, breakthrough initiatives, with an initial focus on eating disorders and anorexia nervosa.

The Imperial Centre for Psychedelic Research and the CIPPRes Clinic are leading psychedelic research in the United Kingdom, building on over a decade of pioneering work in this area carried out at Imperial College London, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression.